XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Summary of Stock Option Activity A summary of equity award activity under the Company’s equity plans and related information is as follows (in thousands, except share, price and year data):
 Shares
available for
grant		Outstanding
Stock
Options		Weighted-
average
exercise
Price		Weighted-
average
remaining
contractual
life (years)		Aggregate
intrinsic
value
Balance as of December 31, 2021
3,880,274 14,940,182 $5.19 6.69$182,843 
Shares authorized1,519,241 
Options granted(109,800)109,800 13.29 
Options exercised— (429,639)2.06 
Options cancelled221,176 (221,176)5.54 
Restricted Stock Units (“RSUs”) granted(897,224)
RSUs cancelled7,525 
Balance as of March 31, 2022
4,621,192 14,399,167 $5.34 6.54$93,993 
Vested and exercisable as of March 31, 2022
8,575,879 $2.26 4.88$72,090 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The following table summarizes the Black-Scholes option pricing model weighted-average assumptions used in estimating the fair value of stock options granted to employees during the three months ended March 31, 2022 and 2021.
Three Months Ended March 31,
20222021
Expected term (in years)
6.06.0
Expected volatility
49.0 %49.2 %
Risk-free interest rate
1.20 %1.09 %
Expected dividend yield— %— %
Three Months Ended March 31,
2022
Expected term (in years)
0.5 - 2.0
Expected volatility
45% - 57%
Risk-free interest rate
0.10% - 0.51%
Expected dividend yield— %
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
RSU activity for the three months ended March 31, 2022 was as follows:

SharesWeighted-Average Grant Date Fair Value per Share
Unvested balance as of December 31, 2021
18,750$22.04
Granted
897,224$11.50
Vested
—$—
Forfeited
(7,525)$13.29
Unvested balance as of March 31, 2022
908,449$11.70
Share-based Payment Arrangement, Expensed and Capitalized, Amount
Stock-based compensation expense included in the condensed statements of operations was as follows (in thousands):
For the Three Months Ended March 31,
20222021
Cost of revenue
$276 $85 
Research and development
1,555 399 
Sales and marketing
1,134 189 
General and administrative
870 235 
Total stock-based compensation expense
$3,835 $908